H.C. Wainwright raised the firm’s price target on Dianthus (DNTH) to $47 from $40 and keeps a Buy rating on the shares. The firm sees a “catalyst-rich” 2026 for the company.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating
- Dianthus price target raised to $62 from $60 at Oppenheimer
- Dianthus Therapeutics Reports Q3 2025 Financial Results
- Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Dianthus reports Q3 EPS (97c), consensus (90c)